Prophylactic treatment of migraine with botulinum toxin type A: a pharmacoeconomic analysis in a community setting

References

• Lipton R B, Stewart W F, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41: 646–657
   PubMed Web of Science ®Google Scholar
• Leonardi M, Steiner T J, Scher A T, et al. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). Journal of Headache and Pain 2005; 6: 429–440
   PubMedGoogle Scholar
• Lipton R B, Pan J. Is migraine a progressive brain disease?. Journal of the American Medical Association 2004; 29: 493–494
   Google Scholar
• Welch K M, Nagesh V, Aurora S K, et al. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness?. Headache 2001; 41: 629–637
   PubMed Web of Science ®Google Scholar
• Kruit M C, van Buchem M A, Hofman P A, et al. Migraine as a risk factor for subclinical brain lesions. Journal of the American Medical Association 2004; 291: 427–434
   PubMed Web of Science ®Google Scholar
• Welch K M, Goadsby P J. Chronic daily headache: nosology and pathophysiology. Current Opinion in Neurology 2002; 15: 287–295
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004; 62: 788–790
   PubMed Web of Science ®Google Scholar
• Silberstein S D, Lipton R B. Chronic daily headache. Current Opinion in Neurology 2000; 13: 277–283
   PubMed Web of Science ®Google Scholar
• Silberstein S D. Transformed and chronic migraine. In: Goadsby P, Silberstien S, Dodick D, Editors. Chronic Daily Headache for Clinicians. Hamilton, Ontario: BC Decker, Inc., 2005; 21–56
   Google Scholar
• Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24((Suppl 1))9–160
   PubMed Web of Science ®Google Scholar
• Silberstein S D, Olesen J, Bousser M- G, et al. The International Classification of Headache Disorders, 2nd Edition (ICHD-II)—revision of criteria for 8.2 Medication—overuse headache. Cephalalgia 2005; 25: 460–465, [Erratum. Cephalalgia 2006; 26: 360].
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee, Olesen J, Bousser M- G, Diener H -C, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 742–746
   PubMed Web of Science ®Google Scholar
• Ferrari M D. The economic burden of migraine to society. PharmacoEconomics 1998; 13: 667–676
   PubMed Web of Science ®Google Scholar
• Hu X H, Markson L E, Lipton R B, et al. Burden of migraine in the United States: disability and economic costs. Archives of Internal Medicine 1999; 159: 813–818
   PubMed Web of Science ®Google Scholar
• Badia X, Magaz S, Gutierrez L, et al. The burden of migraine in Spain: beyond direct costs. PharmacoEconomics 2004; 22: 591–603
   PubMed Web of Science ®Google Scholar
• Clouse J C, Osterhaus J T. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Annals of Pharmacotherapy 1994; 28: 659–664
   PubMed Web of Science ®Google Scholar
• Krymchantowski A V. Overuse of symptomatic medications among chronic (transformed) migraine patients: profile of drug consumption. Arquivos de Neuro-psiquiatria 2003; 61: 43–47
   PubMed Web of Science ®Google Scholar
• Bigal M E, Rapoport A M, Sheftell F D, et al. Transformed migraine and medication overuse in a tertiary headache centre—clinical characteristics and treatment outcomes. Cephalalgia 2004; 24: 483–490
   PubMed Web of Science ®Google Scholar
• Ward T N. Medication overuse headache. Primary Care 2004; 31: 369–380
   PubMed Web of Science ®Google Scholar
• Zwart J A, Dyb G, Hagen K, et al. Analgesic overuse among subjects with headache, neck, and low-back pain. Neurology 2004; 62: 1540–1544
   PubMed Web of Science ®Google Scholar
• Kavuk I, Katsarava Z, Selekler M, et al. Clinical features and therapy of medication overuse headache. European Journal of Medical Research 2004; 9: 565–569
   PubMed Web of Science ®Google Scholar
• Fanciullacci M, De Cesaris F. Preventing chronicity of migraine. Journal of Headache and Pain 2005; 6: 331–333
   PubMedGoogle Scholar
• Diener H, Limmroth V, Katsarava Z. Medication-overuse headache. In:. Chronic Daily Headache for Clinicians., P Goadsby, S Silberstein, D Dodick. BC Decker, Inc., Hamilton, Ontario 2005; 117–127
   Google Scholar
• Sances G, Ghiotto N, Loi M, et al. A CARE: pathway in medication-overuse headache: the experience of the Headache Centre in Pavia. Journal of Headache and Pain 2005; 6: 307–309
   PubMedGoogle Scholar
• Obermann M, Bartsch T, Katsarava Z. Medication overuse headache. Expert Opinion on Drug Safety 2006; 5: 49–56
   PubMed Web of Science ®Google Scholar
• Silberstein S D. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55: 754–762
   PubMed Web of Science ®Google Scholar
• Silberstein S D, Winner P K, Chmiel J J. Migraine preventive medication reduces resource utilization. Headache 2003; 43: 171–178
   PubMed Web of Science ®Google Scholar
• Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003; 43((Suppl 1))S16–S24
   PubMed Web of Science ®Google Scholar
• Aoki K R. Pharmacology and immunology of botulinum neurotoxins. International Ophthalmology Clinics 2005; 45: 25–37
   PubMedGoogle Scholar
• Aoki K R. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003; 43: 9–15
   PubMed Web of Science ®Google Scholar
• Durham P L, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004; 44: 35–42
   PubMed Web of Science ®Google Scholar
• Cui M, Khanijou S, Rubino J, et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107: 125–133
   PubMed Web of Science ®Google Scholar
• Mathew N T, Frishberg B M, Gawel M, et al. Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005; 45: 293–307
   PubMed Web of Science ®Google Scholar
• Silberstein S D, Stark S R, Lucas S M, et al. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clinic Proceedings 2005; 80: 1126–1137
   PubMed Web of Science ®Google Scholar
• Dodick D W, Mauskop A, Elkind A H, et al. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005; 45: 315–324
   PubMed Web of Science ®Google Scholar
• Silberstein S, Mathew N, Saper J, et al. Botulinum toxin type A as a migraine preventive treatment. Headache 2000; 40: 445–450
   PubMed Web of Science ®Google Scholar
• Laloux P, Vakaet A, Monseu G, et al. Subcutaneous sumatriptan compared with usual acute treatments for migraine: clinical and pharmacoeconomic evaluation. Acta Neurologica Belgica 1998; 98: 332–341
   PubMed Web of Science ®Google Scholar
• Lofland J H, Johnson N E, Batenhorst A S, et al. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective. Archives of Internal Medicine 1999; 159: 857–863
   PubMed Web of Science ®Google Scholar
• Williams P, Dowson A J, Rapoport A M, et al. The cost effectiveness of stratified care in the management of migraine. PharmacoEconomics 2001; 19: 819–829
   PubMed Web of Science ®Google Scholar
• Bigal M E, Rapoport A M, Bordini C A, et al. Burden of migraine in Brazil: estimate of cost of migraine to the public health system and an analytical study of the cost-effectiveness of a stratified model of care. Headache 2003; 43: 742–754
   PubMed Web of Science ®Google Scholar
• Schim J. Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients. Current Medical Research and Opinion 2004; 20: 49–53
   PubMed Web of Science ®Google Scholar
• McAllister P. Improvement of symptoms and reduction in headache medication usage in patients treated with botulinum toxin type A. Journal of Medical Economics 2004; 7: 1–10
   Google Scholar
• Brown J S, Papadopoulos G, Neumann P J, et al. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment. Headache 2005; 45: 1012–1022
   PubMed Web of Science ®Google Scholar
• Mushet G R, Miller D, Clements B, et al. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine. Headache 1996; 36: 137–143
   PubMed Web of Science ®Google Scholar
• Lofland J H, Kim S S, Batenhorst A S, et al. Cost-effectiveness and cost–benefit of sumatriptan in patients with migraine. Mayo Clinic Proceedings 2001; 76: 1093–1101
   PubMed Web of Science ®Google Scholar
• Sculpher M, Millson D, Meddis D, et al. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study. PharmacoEconomics 2002; 20: 91–100
   PubMed Web of Science ®Google Scholar
• Vicente-Herrero T, Burke T A, Lainez M J. The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal service employees from an employer perspective. Current Medical Research and Opinion 2004; 20: 1805–1814
   PubMed Web of Science ®Google Scholar
• McCormack P L, Foster R H. Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine. PharmacoEconomics 2005; 23: 1283–1298
   PubMed Web of Science ®Google Scholar
• Thompson M, Gawel M, Desjardins B, et al. An economic evaluation of rizatriptan in the treatment of migraine. PharmacoEconomics 2005; 23: 837–850
   PubMed Web of Science ®Google Scholar
• Blumenfeld A M, Binder W, Silberstein S D, et al. Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache 2003; 43: 884–891
   PubMed Web of Science ®Google Scholar
• Stang P, Cady R, Batenhorst A, et al. Workplace productivity. A review of the impact of migraine and its treatment. PharmacoEconomics 2001; 19: 231–244
   PubMed Web of Science ®Google Scholar
• Edmeads J, Mackell J A. The economic impact of migraine: an analysis of direct and indirect costs. Headache 2002; 42: 501–509
   PubMed Web of Science ®Google Scholar
• Pradalier A, Auray J P, El Hasnaoui A, et al. Economic impact of migraine and other episodic headaches in France: data from the GRIM2000 study. PharmacoEconomics 2004; 22: 985–999
   PubMed Web of Science ®Google Scholar
• Adelman J U, Adelman L C, Von Seggern R. Cost-effectiveness of antiepileptic drugs in migraine prophylaxis. Headache 2002; 42: 978–983
   PubMed Web of Science ®Google Scholar
• Coukell A J, Lamb H M. Sumatriptan. A pharmacoeconomic review of its use in migraine. PharmacoEconomics 1997; 11: 473–490
   PubMed Web of Science ®Google Scholar
• Perry C M, Markham A. Sumatriptan. An updated review of its use in migraine. Drugs 1998; 55: 889–922
   PubMed Web of Science ®Google Scholar